How to Read Peptide Research: Understanding Study Design, Animal vs Human Dosing, and Effect Sizes

Peptide research is expanding rapidly, but not all studies carry the same weight. For researchers, clinicians, and informed readers trying to make sense of published findings, understanding how to evaluate study design, interpret dosing across species, and assess effect sizes is essential. This guide outlines core principles for reading peptide literature critically.

The Peptide Register catalogues peptide profiles with structured evidence summaries precisely because raw study data can be misleading without proper context. This post is designed to help readers extract meaningful conclusions from published work and avoid common interpretation errors.

Study Design Hierarchy: Why the Type of Study Matters

Not all evidence is equal. The hierarchy of evidence in biomedical research places systematic reviews and meta-analyses at the top, followed by randomised controlled trials (RCTs), then cohort and case-control studies, and finally case reports and preclinical (animal or in vitro) studies at the base.

Most published peptide research consists of preclinical animal studies or small open-label human trials. Randomised controlled trials in peptide research remain relatively rare outside of established pharmaceutical peptides such as insulin or GLP-1 receptor agonists. This matters because preclinical findings frequently fail to replicate in human trials. Estimates suggest that over 90% of drug candidates that succeed in animal models ultimately fail in human clinical trials.

When reading a peptide study, the first question should always be: what type of study is this? An in vitro study showing peptide activity in a cell line tells you something about mechanism, but very little about clinical relevance. A rodent study with positive results is a hypothesis-generating signal, not proof of efficacy in humans.

For context on how different peptide categories carry different evidence bases, see the Peptide Register's comparison of collagen peptides versus bioactive signalling peptides.

Translating Animal Doses to Human Equivalent Doses

One of the most common errors in interpreting peptide research is assuming that a dose used in a mouse or rat study maps directly to a human dose by simple weight scaling. Animal-to-human dose conversion requires allometric scaling, not simple weight-based arithmetic. The FDA's standard guidance uses body surface area (BSA) normalization, which accounts for differences in metabolic rate across species.

Under BSA scaling, a mouse dose in mg/kg is typically divided by approximately 12.3 to estimate a human equivalent dose (HED) in mg/kg. For rats, the conversion factor is approximately 6.2. This means a dose of 10 mg/kg in a mouse corresponds to roughly 0.81 mg/kg in a human, not 10 mg/kg. A dose of 10 mg/kg in a rat corresponds to approximately 1.6 mg/kg in a human using FDA body surface area conversion.

These conversion factors are approximations and do not account for species-specific differences in peptide absorption, distribution, metabolism, or receptor binding affinity. Bioavailability can differ substantially between species and between routes of administration. The Peptide Register's overview of peptide bioavailability across delivery routes provides further context on how administration method affects peptide pharmacokinetics.

Effect Sizes, Statistical Significance, and Clinical Relevance

A study can report statistically significant results (p < 0.05) while showing an effect so small that it has no practical or clinical meaning. Statistical significance and clinical significance are not the same thing. Effect size, measured by metrics such as Cohen's d, tells you the magnitude of a difference between groups. An effect size below 0.2 is generally considered negligible, while values above 0.8 indicate a large effect.

Many peptide studies report p-values without reporting effect sizes or confidence intervals, making it difficult to assess practical relevance. Small sample sizes, which are common in early-phase peptide trials, can produce wide confidence intervals and unstable effect estimates. A study with 10 participants per group may show a large effect that fails to replicate in a larger trial.

Readers should also watch for surrogate endpoints versus clinical endpoints. A peptide study might show a change in a biomarker (such as a hormone level or inflammatory marker) without demonstrating any change in a meaningful clinical outcome. Surrogate endpoints are useful for understanding mechanism but do not confirm therapeutic benefit.

Red Flags and Quality Indicators in Peptide Literature

Several indicators can help distinguish higher-quality peptide studies from lower-quality ones. Pre-registration of a trial (for example on ClinicalTrials.gov) reduces the risk of selective reporting. Peer review in an indexed journal, while imperfect, provides a baseline quality filter. Adequate control groups, blinding, and randomization are hallmarks of rigorous study design.

Red flags include studies with no control group, studies funded solely by a peptide manufacturer without independent replication, and studies that report only positive outcomes without discussing adverse events. For a broader discussion of what is known about peptide safety data, see the Peptide Register's coverage of peptide safety, side effects, and long-term risks.

Over 90% of drug candidates that show efficacy in animal models fail when tested in human clinical trials. This attrition rate underscores the importance of treating preclinical peptide findings as preliminary signals rather than established evidence. The gap between promising animal data and validated human outcomes remains wide across biomedical research, and peptide science is no exception.

The Peptide Register's peptide database and glossary are designed to help readers navigate these distinctions by providing structured, evidence-graded profiles for individual peptides.